Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
The price of Prime Medicine Inc (NASDAQ: PRME) closed at $4.04 in the last session, up 8.02% from day before closing price of $3.74. In other words, the price has increased by $8.02 from its previous closing price. On the day, 4.69 million shares were traded. PRME stock price reached its highest trading level at $4.07 during the session, while it also had its lowest trading level at $3.51.
Ratios:
We take a closer look at PRME’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 4.78 and its Current Ratio is at 4.78. In the meantime, Its Debt-to-Equity ratio is 1.13 whereas as Long-Term Debt/Eq ratio is at 1.07.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Aug 01 ’25 when NELSEN ROBERT bought 3,030,300 shares for $3.30 per share. The transaction valued at 9,999,990 led to the insider holds 6,230,300 shares of the business.
ARCH Venture Partners XII, LLC bought 3,030,300 shares of PRME for $9,999,990 on Aug 01 ’25. The 10% Owner now owns 6,230,300 shares after completing the transaction at $3.30 per share. On Aug 01 ’25, another insider, ARCH Venture Partners X, LLC, who serves as the 10% Owner of the company, bought 3,030,300 shares for $3.30 each. As a result, the insider paid 9,999,990 and bolstered with 6,230,300 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PRME now has a Market Capitalization of 696883840 and an Enterprise Value of 493295520. For the stock, the TTM Price-to-Sale (P/S) ratio is 141.13 while its Price-to-Book (P/B) ratio in mrq is 4.96. Its current Enterprise Value per Revenue stands at 128.262 whereas that against EBITDA is -2.466.
Stock Price History:
The Beta on a monthly basis for PRME is 2.41, which has changed by -0.102222204 over the last 52 weeks, in comparison to a change of 0.20277917 over the same period for the S&P500. Over the past 52 weeks, PRME has reached a high of $5.62, while it has fallen to a 52-week low of $1.11. The 50-Day Moving Average of the stock is 46.10%, while the 200-Day Moving Average is calculated to be 51.12%.
Shares Statistics:
According to the various share statistics, PRME traded on average about 3.77M shares per day over the past 3-months and 4438080 shares per day over the past 10 days. A total of 131.16M shares are outstanding, with a floating share count of 52.90M. Insiders hold about 60.67% of the company’s shares, while institutions hold 28.85% stake in the company. Shares short for PRME as of 1752537600 were 21664197 with a Short Ratio of 5.75, compared to 1749772800 on 18480703. Therefore, it implies a Short% of Shares Outstanding of 21664197 and a Short% of Float of 33.51.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
As of right now, 10.0 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is -$0.28, with high estimates of -$0.24 and low estimates of -$0.31.
Analysts are recommending an EPS of between -$1.04 and -$1.37 for the fiscal current year, implying an average EPS of -$1.21. EPS for the following year is -$0.91, with 9.0 analysts recommending between -$0.76 and -$1.4.
Revenue Estimates
A total of 11 analysts have provided revenue estimates for PRME’s current fiscal year. The highest revenue estimate was $50M, while the lowest revenue estimate was $1.45M, resulting in an average revenue estimate of $14.24M. In the same quarter a year ago, actual revenue was $2.98M
